COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.

Protocol No
ADICET-ADI-001-BCELL
Principal Investigator
Mehdi Hamadani
Phase
I
Summary
Evaluate ADI-001 at different dose levels and in combination with Interleukin-2 (IL-2), an approved cancer treatment that helps your immune system fight cancers.
Description
A Phase 1 Study of ADI-001 in B Cell Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL